Work

CLO24-079: Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents (ESAs)

Year: 2024

Type: article

Source: Journal of the National Comprehensive Cancer Network

DOI: 10.6004/jnccn.2023.7228

Authors: Yazan Madanat, Michael R. Savona, Mikkael A. Sekeres, Uwe Platzbecker, Valeria Santini, Pierre Fenaux, Maria Diez-Campelo, David Valcárcel, Tymara Berry, Souria Dougherty, Sheetal Shah, Libo Sun, Ying Wan, Fei Huang, Shyamala Navada, Rami S. Komrokji, Amer M. Zeidan

Institutions: Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, University of Miami, Sylvester Comprehensive Cancer Center, University Hospital Leipzig, University of Florence, Université Paris Cité, Hôpital Saint-Louis, Vall d'Hebron Hospital Universitari, Geron (United States), Moffitt Cancer Center, Yale Cancer Center, Yale University

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4393991571

FWCI:

Cites:

Cited by:

Related to: 10